Compare GGR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGR | ACET |
|---|---|---|
| Founded | 2011 | 1947 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 83.3M |
| IPO Year | 2021 | 2017 |
| Metric | GGR | ACET |
|---|---|---|
| Price | $2.96 | $4.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.83 |
| AVG Volume (30 Days) | 12.9K | ★ 297.5K |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $6.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $0.46 |
| 52 Week High | $5.43 | $9.97 |
| Indicator | GGR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 25.78 |
| Support Level | $2.85 | N/A |
| Resistance Level | $3.33 | $8.54 |
| Average True Range (ATR) | 0.17 | 0.45 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 58.49 | 4.50 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).